Chronic Lymphocytic Leukemia | Topics

 
Various Diagnostic Criteria by PET/CT May Assist in Predicting Richter Syndrome in CLL
January 14, 2021

A recent study revealed that by using standardized uptake value thresholds as determined by 2-[18F]-FDG PET/CT, investigators were able to predict the occurrence of Richter syndrome in patients with CLL.

Jan A. Burger, MD, PhD, on Long-Term Outcomes with Ibrutinib in High-Risk Patients with CLL/SLL
December 07, 2020

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

John N. Allan, MD, on the Impact of First-Line Ibrutinib in Patients with CLL, TP53 Aberrations
December 07, 2020

This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.